Mersana Therapeutics Provides Business Update and AnnouncesĀ Second Quarter 2025 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (A...
Are there broader sector or macro trends that could amplify or dampen the stock's reaction to this business update?
How might the results influence analyst coverage, consensus estimates, and target price revisions?
What is the expected impact of the Q2 results on the company's burn rate and potential need for additional financing?
28 days ago